This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Oral presentation

O112 Trends in transmitted HIV drug resistance among non-B subtypes in the UK

D Chilton^1,3, L Harrison¹, H Green¹, S Lattimore², V Delpech² and D Pillay¹

¹  Medical Research Council Clinical Trials Unit, London, UK

²  Health Protection Agency, London, UK

³  Department of Virology, University College London, London, UK

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):O2doi:10.1186/1758-2652-11-S1-O2

Published:	10 November 2008

First paragraph (this article has no abstract)

Europe is seeing more non-B subtype HIV, reflecting patterns of migration. In France in 2003, 19% of new infections were non-B subtype [1] and UK data showed a rise in infection acquired heterosexually in Africa: 19% in 1992, to 33% in 2006 [2]. With the roll-out of antiretrovirals (ART) in the developing world and use of single dose nevirapine for prevention of mother-to-child transmission, reports of emerging transmitted drug resistance (TDR) among non-B subtypes have followed.